Boehringer Ingelheim Competitors and Similar CompaniesClear all

Boehringer Ingelheim's competitors and similar companies include AstraZeneca and Lilly.

	Boehringer Ingelheim Boehringer Ingelheim International is a pharmaceutical company specializing in animal health, human pharma, and biopharmaceutical contract manufacturing.	AstraZeneca AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.	Lilly Eli Lilly is a company that discovers, develops, manufactures, and markets pharmaceutical products.
Founding Date	Founding Date 1958	Founding Date 1999	Founding Date 1876
Type	Type Subsidiary	Type Public	Type Public
Tags	Tags Healthcare biotech drug development pharma therapy veterinary	Tags Healthcare biotech clinical research drug development oncology pharma	Tags Manufacturing & Industrial diabetes drug development oncology pharma
Locations	Locations Ingelheim am Rhein, DE HQ Ouled Fayet, DZ Munro, AR Macquarie Park, AU Wien, AT Minsk, BY Bruxelles, BE see more	Locations Cambridge, GB HQ Alger, DZ Buenos Aires, AR Macquarie Park, AU Macquarie Park, AU North Ryde, AU Wien, AT see more	Locations Indianapolis, US HQ Buenos Aires, AR Sydney, AU Wien, AT Brussel, BE São Paulo, BR Toronto, CA see more
Employees	Employees 1,2338% increase	Employees 94,300	Employees 47,0009% increase
Valuation ($)	Valuation ($) N/A	Valuation ($) 2.7 b	Valuation ($) 903.4 b
Financial
Revenue (est.)	Revenue (est.) €12.7b (FY, 2023)	Revenue (est.) $58.7b (FY, 2025)	Revenue (est.) $65.2b (FY, 2025)
Cost of goods	Cost of goods €4b (FY, 2023)	Cost of goods $4.9b (FY, 2025)	Cost of goods $11.1b (FY, 2025)
Gross profit	Gross profit €8.7b (FY, 2023)	Gross profit $54.2b (FY, 2025)	Gross profit $54.1b (FY, 2025)
Net income	Net income €5.8b (FY, 2023)	Net income $10.2b (FY, 2025)	Net income $20.6b (FY, 2025)
Operating ⚠
Countries	Countries N/A	Countries 130 (FY, 2021)	Countries 120 (FY, 2021)